Navigation


RSS: Latest News Feed



Small batch of swine flu vaccines pulled in Canada

Nov 24, 2009 @ 01:15 AM, Health, Meera Selva

Text Size: Make Text Size Smaller Make Text Size Bigger Reset
Email Friend
Print
Digg
Delicious
MySpace
Facebook
Twitter
Favorites
StumbleUpon

Google
Live

You need Flash player 8+ and JavaScript enabled to view this video.

LONDON — Canadian doctors have been advised not to use a batch of 170,000 swine flu vaccines after six reports of serious allergic reactions among recipients, but there are no similar reports from other countries, pharmaceuticals company GlaxoSmithKline PLC said Tuesday.

Authorities routinely monitor vaccines for any signals of problems, such as the allergic reactions that do occur, rarely, every year. Company spokeswoman Gwenan White said that GlaxoSmithKline advised medical staff in Canada ast week to refrain from using one batch of the vaccine while they look into reports that that it might have caused more allergic reactions than normal.

Six people in Canada had suffered an allergic reaction, said Tim Vail, the spokesman for Canada's health minister. The batch contained about 170,000 doses. It was not immediately clear how many had been administered, although Vail said the majority had been.

"We're not seeing any thing wild or spooky or crazy about our vaccine at all," Vail said, arguing it may have been a statistical anomaly that the reactions occurred.

GlaxoSmithKline is only investigating the one batch of its swine flu vaccine in Canada. White said no other doses of its swine flu vaccine around the world are affected.

White said U.K.-based GlaxoSmithKline wrote to Canadian health care professionals advising them to stop using the batch on Nov. 18. She says a total of 7.5 million doses of the vaccine have been distributed in Canada.

Dr. Joel Kettner, Manitoba's chief medical officer of health has said they are being cautious and are following the advice. He urged people not to be alarmed, saying that any allergic reactions occur shortly after inoculation, don't last long and have not led to long-term health problems.

The provincial Alberta government was also holding back the vaccine, although it had not seen a jump in reactions.

GlaxoSmithKline is the world's second largest drug maker by revenue. Its shares were up 0.08 percent on the London stock exchange at 1,278.50p ($21.19)

Associated Press Writer Rob Gillies in Toronto contributed to this report.

Source: The Associated Press


Bookmark and Share
« Back to Health News

Related News

  • Experts Say Swine Flu Mutations Do Not Warrant New Alarm Nov 24, 2009 @ 01:15 AM

    The World Health Organization tried this week to dampen fears about mutations seen in the swine flu virus in several countries, noting that both mutations had been found in very few people.


  • Drug resistant H1N1 no major change in virus-WHO Nov 24, 2009 @ 01:15 AM

    GENEVA, Nov 26 (Reuters) - Tamiflu resistance in some H1N1 patients with badly weakened immune systems does not seem to reflect a major change in the virus' susceptibility to the frontline drug, the World Health Organisation said on Thursday.


  • Vaccine system remains antiquated Nov 24, 2009 @ 01:15 AM

    After a lethal bird flu virus emerged in Asia, U.S. officials launched an intense effort to build new defenses against a pandemic, including replacing an antiquated vaccine system, which depends on millions of chicken eggs.


  • US slow to build new flu defenses Nov 24, 2009 @ 01:15 AM

    After a lethal bird flu virus emerged in Asia, U.S. officials launched an intense effort to build new defenses against a pandemic, including replacing an antiquated vaccine system, which depends on millions of chicken eggs.


  • Officials Defend Handling of Flu Vaccine Nov 24, 2009 @ 01:15 AM

    As a nationwide shortage of swine flu vaccine stretched into its sixth week, federal health officials defended how they handled the program, arguing that the roots of the shortage were beyond their control and that they had made the right decisions on matters they could affect.